Nordic Nanovector Highlights Novel Humanized Anti-CD37 Therapeutic Antibody Candidates for B-cell Malignancies or B-cell-driven Autoimmune Disorders at ASH Annual Meeting

03 Nov 2022 14:01 CET

Nordic Nanovector Highlights Novel Humanized Anti-CD37 Therapeutic Antibody
Candidates for B-cell Malignancies or B-cell-driven Autoimmune Disorders at ASH
Annual Meeting

Oslo, Norway, 3 November 2022

Nordic Nanovector ASA (OSE: NANOV) ("Nordic Nanovector" or the "Company")
announces the progress it has made in designing and developing a portfolio of
novel and potent humanized anti-CD37 monoclonal antibodies with potential for
treating B-cell malignancies or B-cell-driven autoimmune disorders.

Details of the Company's progress in engineering this portfolio are included in
two abstracts published today for presentation as posters at the 64[th] American
Society of Hematology (ASH) Annual Meeting & Exposition (10-13 December 2022 in
New Orleans, LA, USA). The abstracts will also be published online in a November
supplemental issue of Blood, published by The American Society of Hematology.

The abstracts describe how, through antibody engineering, Nordic Nanovector has
developed several humanized anti-CD37 monoclonal antibodies and demonstrated in
preclinical studies their enhanced effector mechanisms, such as antibody
-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular
phagocytosis (ADCP) and longer half-life in the blood.

CD37 is a protein abundant on the surface of B cells but absent in
haematopoietic stem cells and plasma cells. Its expression pattern makes it
attractive as a therapeutic target for B-cell malignancies, including non
-Hodgkin lymphomas and chronic lymphocytic Leukemia and for B-cell-driven
autoimmune disorders, especially where an alternative to standard anti-CD20
immunotherapy is sought.

Jostein Dahle, Co-founder and CSO of Nordic Nanovector, commented: "We are
pleased to present at ASH the initial findings from our preclinical studies with
our novel humanized anti-CD37 antibody portfolio. These antibodies have been
designed to be highly selective for CD37 on B cells and shown to be potent at
depleting these cells as well as enduring in the circulation. There is a
significant unmet clinical need for new therapeutic approaches for patients with
B-cell-driven diseases who do not respond to anti-CD20 therapies. The
encouraging preclinical results we will present at ASH support the further
development of these candidates for B-cell malignancies or B-cell-driven
autoimmune disorders."

Details of the abstracts to be presented at ASH are as follows:

Abstract 1351

Abstract title:                 NNV024, a Humanized Anti-CD37 Antibody with
Enhanced ADCC and Extended Plasma Half-Life for the Treatment of B-Cell
Malignancies

Authors:                        R. Generalov et al.

Session Name:              605. Molecular Pharmacology and Drug Resistance:
Lymphoid Neoplasms: Poster I

Date:                            Saturday, December 10

Presentation Time:        5:30 PM - 7:30 PM Eastern time

Location:                       Ernest N. Morial Convention Center, Hall D

Abstract 2679

Abstract title:                 B-Cell Targeting Anti-CD37 Humanized Antibodies
Engineered for Potent Effector Functions and Extended Plasma Half-Life

Authors:                        E. Fiorito et al.

Session Name:              605. Molecular Pharmacology and Drug Resistance:
Lymphoid Neoplasms: Poster II

Session Date:               Sunday, 11 December

Presentation Time:        6:00 PM - 8:00 PM Eastern time

Location:                      Ernest N. Morial Convention Center, Hall D

IR enquiries

Malene Brondberg, interim CEO & CFO
Cell: +44 7561 431 762
Email: ir@nordicnanovector.com

Media Enquiries

Frazer Hall / Mark Swallow (MEDiSTRAVA Consulting)
Tel: +44 203 928 6900
Email: nordicnanovector@medistrava.com

About Nordic Nanovector:

Nordic Nanovector is committed to develop and deliver innovative therapies to
patients to address major unmet medical needs and advance cancer care. The
Company's clinical- and preclinical-stage pipeline includes:

· Betalutin® and Humalutin®, both CD37-targeting radioimmunotherapies
incorporating the beta emitter lutetium-177 to treat non-Hodgkin's lymphoma
(NHL);
· Alpha37, a CD37-targeting radioimmunotherapy candidate incorporating the
alpha-emitting radionuclide lead-212, currently being explored with partner
Oranomed for chronic lymphocytic leukaemia;
· Multiple fully humanized anti-CD37 antibodies with potential in
haematological cancers and autoimmune diseases; and
· A CD37 DOTA CAR-T cell opportunity in haematological cancers, which is being
advanced via a research collaboration with the University of Pennsylvania.

Further information can be found at
www.nordicnanovector.com (https://nam10.safelinks.protection.outlook.com/?url=ht
t
p%3A%2F%2Fwww.nordicnanovector.com%2F&data=05%7C01%7Cmark.swallow%40medistrava.c
o
m%7C6e166f0d8ab045baa74c08da813d9127%7C5c24475f929349d0b4e1ba6d190e92f9%7C0%7C0%
7
C637964398695667184%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIi
L
CJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=CtQu5sHd4a%2Bio0LyYmQHR0ptgo
T
KcIhc5hpqa4eLFZk%3D&reserved=0).

Forward-looking statements

This press release contains certain forward-looking statements relating to inter
alia to the business and strategies, financial performance and results of the
Company. Forward-looking statements concern future circumstances and results and
other statements that are not historical facts. These statements are based on
Nordic Nanovector's current expectations and are subject to uncertainty and
changes in circumstances. Any forward-looking statements contained in this
release, including assumptions, opinions and views of Nordic Nanovector or cited
from third party sources, are subject to risks, uncertainties and other factors
that may cause actual results and events to be materially different from those
expected or implied by the forward-looking statements. Nordic Nanovector cannot
provide any assurance that the assumptions underlying such forward-looking
statements are free from errors nor accept any responsibility for the future
accuracy of opinions expressed in this release or the actual occurrence of any
forecasted developments. Nordic Nanovector disclaims any obligation to update or
revise any forward-looking statements, whether as a result of new information,
future events or otherwise.

The terms "anticipates", "assumes", "believes", "can", "could", "estimates",
"expects", "forecasts", "intends", "may", "might", "plans", "should",
"projects", "targets", "will", "would" or, in each case, their negative, or
other variations or comparable terminology are used to identify forward-looking
statements. There are a number of factors that could cause actual results and
developments to differ materially from those expressed or implied in the forward
-looking statements. Factors that could cause these differences include, but are
not limited to, risks associated with implementation of Nordic Nanovector's
strategy, risks and uncertainties associated with the development and/or
approval of Nordic Nanovector's product candidates, ongoing and future clinical
trials and expected trial results technology changes and new products in Nordic
Nanovector's potential market and industry, Nordic Nanovector's freedom to
operate (competitors patents) in respect of the products it develops, the
ability to develop new products and enhance existing products, the impact of
competition, changes in general economy and industry conditions, and
legislative, regulatory and political factors.

More information:
Access the news on Oslo Bors NewsWeb site